Scheduling Order Entered in AbbVie v. Amgen

AbbVie v. Amgen (adalimumab)  •  U.S. Biosimilar Litigation News

On Thursday, Judge Robinson entered a scheduling order in the AbbVie v. Amgen (adalimumab) case.  Among other things, the order sets a 20-day bench trial beginning November 4, 2019. The order also establishes a number of discovery and hearing deadlines that are somewhat different than those initially proposed before the Rule 16 conference.  Summary judgment motions will not be permitted absent a jury demand.

Stay tuned to Big Molecule Watch for further updates.

Download PDF

Comments are closed.